Subscribe

Michael Bonney, CEO, Cubist Pharmaceuticals

Articles by Michael Bonney, CEO, Cubist Pharmaceuticals

Bringing New Science, and New Partners, Into the Drug Development Process

ByMichael Bonney, CEO, Cubist Pharmaceuticals

January 2nd 2011

Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market

Latest Updated Articles

Bringing New Science, and New Partners, Into the Drug Development Process
Published: January 2nd 2011 | Updated:

Trending on Pharmaceutical Commerce

TrumpRx Launches With MFN-Based Drug Discounts

FTC–Express Scripts Settlement Targets PBM Rebates, Transparency, and Patient Drug Costs

The Great Repricing: Commercial Channel Under Pressure

Pharma's Year of Two Halves

Your Copay Program Is Protecting Access. Is It Also Protecting Gross-to-Net?